IgA肾病湿热证的血清蛋白质组学研究  

Serum proteomics study on IgA nephropathy with Shire syndrome

作　　者：刘垠浩 王丽萍[2] 

机构地区：[1]漳州市中医院,福建漳州363000 [2]南京军区福州总医院,福建福州350003

出　　处：《中医临床研究》2014年第14期7-10,共4页Clinical Journal Of Chinese Medicine

摘　　要：目的:应用表面加强激光解析电离-飞行时间-质谱(SELDI-TOF-MS)技术,对IgA肾病(IgAN)湿热证患者进行血清蛋白质指纹图谱检测,分析探讨该人群中所表达的特异蛋白,试图从蛋白质组层面寻找与IgA肾病湿热证相关的血清标志物。方法:采集IgA肾病患者的血清样本共29例(湿热证14例,非湿热证15例),同时选择非IgA肾病的湿热证肾病患者血清样本10例和健康人血清样本15例。采用表面增强激光解析离子化蛋白质芯片分析仪实现各组血清蛋白质表达谱的检测,后运用Biomarker WizardTM和Biomarker PatternsTM软件进行数据分析,最终识别IgA肾病湿热证特异表达的蛋白质,并建立证候决策树模型。结果:IgA肾病湿热证组与非湿热证组之间共检出有7个蛋白峰具有显著差异(P<0.05);IgA肾病湿热证组与非IgA肾病湿热证组之间共检出有4个蛋白峰具有显著差异(P<0.05);IgA肾病湿热证组与健康对照组之间共检出有5个蛋白峰具有显著差异(P<0.05);综合以上各组对比结果,并结合统计学分析证实,M/Z(质荷比)为4987.92所代表的"Beta-defensin 33蛋白"可能是IgA肾病湿热证的特异血清蛋白标志物。经筛选以M/Z为1092.71等11个蛋白峰组成的证候决策模型能很好地将IgA肾病湿热证区分出来,该模型的敏感性为92.86%,特异性为87.50%。进一步对此决策模型进行盲法验证,结果其敏感性为90.00%,特异性为86.67%。结论:IgA肾病湿热证的发生发展,可能是以M/Z为4987.92所代表的"Beta-defensin 33蛋白"的差异表达为物质基础的,同时建立了分子生物学证候决策树模型。Objective： By applying the technology of SELDI-TOF-MS to detect the serum protein fingerprints of IgA nephropathy（IgAN） patients, analyze the serum specific proteins expressed by the IgA nephropathy patients who are diagnosed with Shire syndrome, and seek the serum markers of IgA nephropathy with Shire syndrome from the proteome level. Methods： Collect twenty-nine serum samples from IgA nephropathy patients （fourteen samples with Shire syndrome, fifteen samples with non-Shire syndrome）. Collect ten serum samples from non-IgA nephropathy patients with Shire syndrome and fifteen serum samples from healthy persons. Apply the surface enhanced laser desorption/ionization-time of flight （SELDI-TOF） protein-chip to research each separate sample of serum proteomics, and then use the Softwares of Biomarker WizardTM and Biomarker WizardTM to make data analysis. In the end, the special serum protein of IgA nephropathy with Shire syndrome can be identified. Moreover, we also create the syndrome decision model. Results： Totally, seven difference protein peaks between Shire syndrome group and non-Shire syndrome group in IgAN patients （P〈0.05）; and four diffenence protein peaks between IgAN Shire syndrome group and non-IgAN Shire syndrome group （P〈0.05）; there are five difference protein peaks between IgAN Shire syndrome group and healthy person group. Combined to the above-mentions and statistical analysis, the protein of M/Z 4987.92 which mean Beta-defensin 33 protein is likely to be the serum protein markers of IgAN with Shire syndrome. A decision model consisted 11 screened out protein peaks with mass-to-charge ratio of 1092.71 and so on was created. Which could well differentiate the IgAN Shire syndrome, with the sensitivity of 92.86%, specificity of 87.50%. Further blind test for prospective check showed its sensitivity being 90.00%, specificity 86.67%. Conclusion： May be the Beta-defensin 33 protein is material foundation of IgAN Shire syndrome. Molecular biological decision model establis

关 键 词：IgA肾病 SELDI-TOF-MS技术 血清蛋白质组学 湿热证 

分 类 号：R692[医药卫生—泌尿科学]